Tiny Cargo
Tiny Cargo is a Roanoke, Virginia-based biotechnology firm that isolates milk-derived exosomes at industrial scale and licenses a precision drug loading platform to pharmaceutical partners for oral delivery of biologics including monoclonal antibodies, peptides, and RNA therapeutics.
- Company typePrivate
- Founded2018
- HeadquartersRoanoke, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Tiny Cargo does
The Tiny Cargo Company, Inc. is a privately held biotechnology company founded in 2018 as a spinout from Virginia Tech's Fralin Biomedical Research Institute, headquartered in Roanoke, Virginia. The company has developed a proprietary platform for isolating exosomes from bovine milk at industrial scale — concentrations reported as 10,000 to 100,000 times greater than cell-culture supernatant yields — and a precision drug loading technology that achieves over 90% encapsulation efficiency across drug classes including peptides, monoclonal antibodies (up to 200 kDa), antisense oligonucleotides, mRNA, miRNA and small molecules. The platform enables oral bioavailability of biologics that historically required injection, demonstrates natural tissue homing to injured and inflamed sites, reduces first-pass liver filtration from over 90% to approximately 10%, and crosses the blood-brain barrier.
The company operates a B2B platform-licensing and partnership model targeting pharmaceutical and cosmeceutical companies, complemented by raw material sales of pharmaceutical-grade milk exosomes and internal development of a proprietary drug candidate, XOlacta, which uses milk exosomes to deliver the alphaCT11 peptide as an oral cardioprotectant and radioprotectant. Its go-to-market relies on direct enterprise engagement, scientific publications, white papers, and inquiry-based pricing for samples and licensing. In February 2026 the company opened a $1.5 million, 2,000+ square foot purpose-built cGMP-aligned cleanroom manufacturing facility in Roanoke — among the first dedicated exosome advanced manufacturing sites globally — and added six new R&D, manufacturing and regulatory roles. Customers to date are undisclosed; GRAS status from the FDA covers cosmetic and food applications.
The company is led by Founder and President Professor Robert Gourdie (Heywood Fralin Endowed Professor at Virginia Tech), Chairman and CEO Alan Gourdie, CSO Spencer Marsh (originator of the milk exosome isolation process and lead PI on NSF/NIH/DoD-funded programs), and CFO Sherri Cook, with a board including Heywood Fralin, Richard Warburg and dairy bioprocessing advisor Professor Richard Archer. Total disclosed funding exceeds $5 million in non-dilutive federal grants (NSF, NIH, DoD), plus state-backed investment from Virginia Innovation Partnership Corporation's Virginia Venture Partners. March 2026 brought a strategic collaboration with Bio-Sourcing SA (Belgium) to co-develop orally administered monoclonal antibody therapies targeting adalimumab (Humira) and trastuzumab (Herceptin), with Clinical Trial Application submissions targeted for early 2027 and 2028.
Tiny Cargo firmographics
Firmographics- Name
- Tiny Cargo
- Legal name
- The Tiny Cargo Company, Inc.
- Website
- https://tinycargo.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Tiny Cargo is a Roanoke, Virginia-based biotechnology firm that isolates milk-derived exosomes at industrial scale and licenses a precision drug loading platform to pharmaceutical partners for oral delivery of biologics including monoclonal antibodies, peptides, and RNA therapeutics.
- Ownership category
- akta.pro rank
Tiny Cargo industry classification
Industry- Product category
- Drug Delivery Technology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Dry, Condensed, and Evaporated Dairy Product Manufacturing (311514), Dairy Product Manufacturing (3115)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Dairy Products (2020)
- akta.pro primary industry
- Whey Fractionation & Bioactive Ingredient Isolation (α-Lac, Lactoferrin, Immunoglobulins, GMP) (AFAHAGAC)
- akta.pro secondary industries
- Whey, Casein & Milk Protein Ingredient Manufacturing (AFAKAKAF), Human Milk Fortifier (HMF) Manufacturing (Bovine-Derived) (AFAHAHAI)
Keywords
Where Tiny Cargo is headquartered
LocationHeadquarters
- HQ city
- Roanoke
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Tiny Cargo business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain
Revenue model
- Platform Licensing to Pharmaceutical Partners: Licensing access to high-efficiency, functionality-preserving loading technology for pharmaceutical companies seeking to enhance delivery of their own therapeutic candidates. Expert team collaborates with partners to optimize exosome loading and accelerate drug development pipelines.
- Milk Exosome Product Sales: Sale of pharmaceutical-grade milk exosomes for use in drug formulations. Products available at grades suitable for pharmaceutical applications. cGMP-aligned commercial specification achieved.
- Proprietary Drug Development (XOlacta): Development and potential commercialization of proprietary drug candidate XOlacta, an orally-administered cardioprotectant and radioprotectant using alphaCT11 peptide loaded into milk exosomes.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Pharmaceutical Grade Milk Exosomes |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Tiny Cargo product offering
Product offeringCore offering
Tiny Cargo develops and manufactures an industrial-scale drug delivery system based on bovine milk-derived exosomes. It isolates pure, stable exosome concentrate from cow's milk at kilogram scale, then precision-loads therapeutic cargoes (peptides, monoclonal antibodies, RNA therapeutics, ASOs, mRNA, small molecules) into the exosomes at greater than 90% efficiency. Offerings include the pharmaceutical drug loading platform licensed to partners, pharmaceutical-grade milk exosomes sold as a raw input, cosmeceutical-grade exosomes, and the proprietary oral drug candidate XOlacta (alphaCT11 peptide loaded into milk exosomes for cardioprotection and radioprotection).
Product overview
The Tiny Cargo Company offers a portfolio of products centered on its proprietary milk exosome technology. The core offering is the Pharmaceutical Drug Loading Platform, which enables precise encapsulation of therapeutic cargoes (peptides, RNAs, biologics, monoclonal antibodies, small molecules) within industrially-scaled milk-derived exosomes at over 90% efficiency. The lead proprietary drug candidate is XOlacta, which combines these milk exosomes with the αCT11 peptide for cardioprotective and radioprotective applications. The company also supplies Pharmaceutical Grade Milk Exosomes as a raw material for pharmaceutical partners, and Cosmeceutical Milk Exosomes for skincare formulations. The platform leverages milk exosomes' natural ability to survive gastric degradation, cross the gut lining, and home to injured tissue.
Differentiator
Problem solved
Functional benefit
Brands
- XOlacta: Proprietary drug product containing alphaCT11 peptide loaded into milk exosomes, being developed as an orally-administered cardioprotectant and radioprotectant.
Products and services
- XOlacta XOlacta is Tiny Cargo's first-in-class proprietary drug candidate, combining milk-derived exosomes loaded with the alphaCT11 peptide. It is being advanced as an orally administered cardioprotectant and systemically-effective radioprotectant designed to reduce cardiac injury following myocardial infarction and to protect healthy cells during radiation therapy. The alphaCT11 peptides are delivered directly to cells via milk exosomes, arresting the bystander effect to prevent the cascade of cell death and fibrosis. XOlacta is being developed for healthcare providers and patients requiring cardioprotection post myocardial infarction, radioprotection during cancer treatment, and medical countermeasures for radiation exposure.
- Pharmaceutical Drug Loading Platform Licensed platform enabling precise encapsulation of peptides, RNAs, biologics, and small molecules within milk exosomes, purpose-designed for pharmaceutical partners developing next-generation therapeutics. The platform achieves greater than 90% loading efficiency across drug classes including peptide therapeutics, monoclonal antibodies up to 150 kDa, antisense oligonucleotides, mRNA, miRNA, and small molecules, and combines natural biocompatibility with targeted delivery via oral administration. Tiny Cargo's expert team collaborates with partners to optimize exosome loading and accelerate drug development pipelines.
- Pharmaceutical-Grade Milk Exosomes Industrially-scaled milk-derived exosomes isolated from bovine milk using Tiny Cargo's proprietary process, available at grades suitable for pharmaceutical applications and serving as the foundational delivery vehicle for the company's therapeutic platform. The product achieves cGMP-aligned commercial specification, is offered at quote-based pricing, and is supplied to pharmaceutical partners through inquiry-based sales.
- Cosmeceutical Milk Exosomes Milk-derived exosomes for cosmetic formulations, marketed for enhancing skin health, regeneration, and delivery of active ingredients in skincare applications. Targeted at cosmeceutical companies seeking innovative bioactive ingredients for skin health, anti-aging, and wound healing products, with efficacy supported by published in vivo and in vitro data and GRAS status for milk exosomes under FDA regulations for cosmetic and food-related applications.
Quantifiable outcome
- 40-70% increase in survival rates from single dose of XOlacta when given before or up to 24 hours following radiation exposure
- +5 more outcomes
Companies that use Tiny Cargo
Customer profileSegments4 records
Ideal customer profiles3 records
Tiny Cargo technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Tiny Cargo partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Fralin Biomedical Research Institute at Virginia TechcoreTiny Cargo was spun out from Virginia Tech's Fralin Biomedical Research Institute in 2018. Ongoing research collaborations and affiliation with the institute where founder Robert Gourdie serves as Heywood Fralin Endowed Professor.
- Bio-Sourcing SAcoreStrategic collaboration between Bio-Sourcing SA of Liège, Belgium and The Tiny Cargo Company to co-develop oral monoclonal antibody therapies using goat-milk extracellular vesicles and exosomes. Combines Bio-Sourcing's BioMilk transgenic goat milk production platform with Tiny Cargo's cGMP-ready industrial exosome extraction and loading technology. Initial programs target oral formulations of adalimumab (Humira) for Crohn's disease and trastuzumab (Herceptin) for HER2+ breast cancer, with Clinical Trial Application submissions targeted for early 2027 and 2028 respectively.
- Likarda, Inc.coreStrategic partnership to advance next-generation delivery of biologics, peptides and small molecules. Integrates Likarda's Core-Shell Spherification platform with Tiny Cargo's vesicle-based technologies to address key drug delivery challenges including poor stability, rapid clearance, and lack of localization.
- JLABSminorSpencer Marsh, CSO, has been a member of Johnson & Johnson's JLABS incubator program for life sciences startups.
- Blue Knight IncubatorminorSpencer Marsh, CSO, has been a member of the Blue Knight Incubator for biotechnology startups.
Scale indicators6 records
Recent moves9 records
Expansion highlights6 records
Tiny Cargo competitors and assessment
Company assessmentDirect peers
- Evox Therapeutics: Oxford-based exosome therapeutics company developing engineered extracellular vesicles for drug delivery of nucleic acids, proteins, and small molecules. Most directly comparable to Tiny Cargo as a pure-play exosome drug delivery platform targeting similar pharmaceutical partner use cases.
- Capricor Therapeutics: Clinical-stage biotech developing cell-derived extracellular vesicle therapies (CAP-1002, CAP-2003) for cardiac and inflammatory indications. Comparable in extracellular vesicle approach and use of natural vesicles for therapeutic delivery, with more advanced clinical-stage assets.
- Aruna Bio: Developer of neural cell-derived exosomes (AB126) for neurological indications including stroke and ALS. Comparable as an exosome-based therapeutic platform targeting CNS delivery challenges, directly competing in the "natural vesicles for drug delivery" category.
- ILIAS Biologics: Korean biotech developing engineered exosomes (EXO-LOAD platform) for intracellular protein therapeutic delivery. Directly comparable as a platform company that loads therapeutic cargoes into exosomes for pharmaceutical applications, similar to Tiny Cargo's drug loading platform.
Emerging players
- Bio-Sourcing SA: Belgian biotech using transgenic goats to produce biotherapeutics in milk, including monoclonal antibodies. Direct strategic partner of Tiny Cargo and a partial competitor in the milk-derived therapeutic space — they use goat milk for biologics production while Tiny Cargo isolates exosomes from the same source.
- Rion (previously known as Rion LLC): Clinical-stage company developing purified exosome products (Purified Exosome Product, PEP) for wound healing, cardiac recovery, and aesthetic indications. Comparable in using exosomes as a therapeutic modality, with some cosmeceutical overlap with Tiny Cargo's cosmeceutical line.
- Kimera Labs: Manufacturer of exosome-based products including cosmetic, regenerative, and research-grade exosome isolates from perinatal sources. Comparable to Tiny Cargo's cosmeceutical line and pharmaceutical-grade exosome product sales, with overlap in skin health and topical delivery applications.
- ExoCoBio: South Korea-based exosome company commercializing exosome products for cosmetic and dermatological applications, including the EXOMAGE line. Most directly comparable in the cosmeceutical exosome segment where Tiny Cargo's Cosmeceutical Milk Exosomes compete.
- Direct Biologics: Clinical-stage regenerative medicine company developing extracellular vesicle products (ExoFlo) for inflammatory and immune-mediated conditions. Comparable in using extracellular vesicles as a therapeutic platform with broad anti-inflammatory applications, partially overlapping with Tiny Cargo's targeted homing and inflammation-based delivery claims.
Broad incumbents
- Genevant Sciences: Lipid nanoparticle (LNP) drug delivery platform serving pharmaceutical partners for nucleic acid and mRNA therapeutics, with significant overlap with Roivant/Roche-affiliated LNP technology. Comparable as a delivery technology platform enabling oral/systemic administration of fragile biologics, though using a different (non-exosome) delivery vehicle.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Tiny Cargo social profiles
Digital presenceTiny Cargo compliance and trust
Trust signalCompliance1 record
Tiny Cargo financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tiny Cargo leadership team
Management profileNumber of profiles
Profiles12 records
Tiny Cargo funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tiny Cargo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tiny Cargo
What does Tiny Cargo do?
Tiny Cargo develops and manufactures an industrial-scale drug delivery system based on bovine milk-derived exosomes. It isolates pure, stable exosome concentrate from cow's milk at kilogram scale, then precision-loads therapeutic cargoes (peptides, monoclonal antibodies, RNA therapeutics, ASOs, mRNA, small molecules) into the exosomes at greater than 90% efficiency. Offerings include the pharmaceutical drug loading platform licensed to partners, pharmaceutical-grade milk exosomes sold as a raw input, cosmeceutical-grade exosomes, and the proprietary oral drug candidate XOlacta (alphaCT11 peptide loaded into milk exosomes for cardioprotection and radioprotection).
Is Tiny Cargo a public or private company?
Tiny Cargo is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Tiny Cargo founded?
Tiny Cargo was founded in 2018. It employs 1 to 10 people.
Where is Tiny Cargo based?
Tiny Cargo is headquartered in Roanoke, United States, in the North America region.
How does Tiny Cargo make money?
Three revenue lines are on record. Platform Licensing to Pharmaceutical Partners are the primary driver. The others are milk Exosome Product Sales and proprietary Drug Development (XOlacta).
Who are Tiny Cargo's main competitors?
Direct peers on record are Evox Therapeutics, Capricor Therapeutics, Aruna Bio and ILIAS Biologics. Emerging players are Bio-Sourcing SA, Rion (previously known as Rion LLC), Kimera Labs, ExoCoBio and Direct Biologics. Genevant Sciences is listed as a broad incumbent.
Does Tiny Cargo have an API?
No public API is recorded for Tiny Cargo.
What industry is Tiny Cargo in?
Tiny Cargo's product category is Drug Delivery Technology. Its primary akta.pro industry code is AFAHAGAC, Whey Fractionation & Bioactive Ingredient Isolation (α-Lac, Lactoferrin, Immunoglobulins, GMP), with a secondary code of AFAKAKAF, Whey, Casein & Milk Protein Ingredient Manufacturing. Its NAICS code is 325414 and its SIC code is 2836.